Live
Clinical OMICsHormone Cell Atlas Maps Body’s Chemical MessengersClinical OMICsSHIMMER: Routine Clinical Data Processed Into Scalable Disease State MarkersEndpoints NewsLilly obesity meds Foundayo and Zepbound to gain CVS coverageEli LillyEli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher. - Barron'sIlluminaIllumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research - PR NewswireThermo FisherThermo Fisher Launches E-Gel Power Snap Lite System - Contract PharmaBioPharma DiveGSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’BioWorldBreakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infectionsBioWorldTROP2 ADCs progress into first-line for lung, breast cancersBioWorldLongbio to raise HK$1.4B in Hong Kong IPO for immunology workEndpoints NewsFor wearables, it’s a GLP-1 worldEli LillyCVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo - Fierce Pharma
FierceBiotech Feb 26, 2026

Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial

Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial

Original
Body unavailable. Use the original source.